Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques

Marcio O. Lasaro, Larissa H. Haut, Xiangyang Zhou, Zhiquan Xiang, Dongming Zhou, Yan Li, Wynetta Giles-Davis, Hua Li, Jessica C. Engram, Lauren J. Dimenna, Ang Bian, Marina Sazanovich, Elizabeth M. Parzych, Raj Kurupati, Juliana C. Small, Te Lang Wu, Rachel M. Leskowitz, Nicole R. Klatt, Jason M. Brenchley, David A. GarberMark Lewis, Sarah J. Ratcliffe, Michael R. Betts, Guido Silvestri, Hildegund C. Ertl

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Despite enormous efforts by the scientific community, an effective HIV vaccine remains elusive. To further address to what degree T cells in absence of antibodies may protect against simian immunodeficiency virus (SIV) disease progression, rhesus macaques were vaccinated intramuscularly with a chimpanzee-derived Ad vector (AdC) serotype 6 and then boosted intramuscularly with a serologically distinct AdC vector of serotype 7 both expressing Gag of SIVmac239. Animals were subsequently boosted intramuscularly with a modified vaccinia Ankara (MVA) virus expressing Gag and Tat of the homologous SIV before mucosal challenge with a high dose of SIVmac239 given rectally. Whereas vaccinated animals showed only a modest reduction of viral loads, their overall survival was improved, in association with a substantial protection from the loss of CD4 T cells. In addition, the two vaccinated Mamu-A01 macaques controlled viral loads to levels below detection within weeks after challenge. These data strongly suggest that T cells, while unable to affect SIV acquisition upon high-dose rectal infection, can reduce disease progression. Induction of potent T-cell responses should thus remain a component of our efforts to develop an efficacious vaccine to HIV-1.

Original languageEnglish (US)
Pages (from-to)417-426
Number of pages10
JournalMolecular Therapy
Issue number2
StatePublished - Feb 2011
Externally publishedYes

Bibliographical note

Funding Information:
This work was funded by grants from NIH/DAIDS and institutional grants to the Wistar Institute including a US National Cancer Institute Cancer Core Grant (CA10815) and the Commonwealth Universal Research Enhancement Program from the Pennsylvania Department of Health. We thank Christina Cole for help in preparation of the manuscript. The authors declared no conflict of interest.

Copyright 2018 Elsevier B.V., All rights reserved.


Dive into the research topics of 'Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques'. Together they form a unique fingerprint.

Cite this